Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy

Inclusion Criteria: * Male or Female, age \>18 yrs who have histologically confirmed adenocarcinoma of the colon or rectum (Stage IV) * Presence of metastatic disease with liver as dominant disease-site defined as \>80% tumor body burden confined to liver; less than 60% liver tumor replacement. * Subject is competent and willing to provide written informed consent in order to participate in the study. * Eastern Cooperative Oncology Group (ECOG) performance status is 0-1 or Child-Pugh classification is A or B7. * Multinodular or single nodular tumor 4 cm, patients with bilobar disease who can be treated superselectively in a single session or both lobes able to be treated within 3 weeks. Patient must have at least one tumor lesion that meets the following criteria: lesion can be accurately measured in at least one dimension according to the Modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria. * Pretreatment with two or more lines of chemotherapy containing Fluorouracil (5-FU) or analogue, oxaliplatin, irinotecan ± bevacizumab ±epidermal growth factor receptor (EGFR)-inhibitors, if indicated, for metastatic disease. * No invasion in the blood vessel (hepatic portal, hepatic vein) or bile duct by the computerized axial tomography (CT) or Magnetic Resonance (MR) Imaging. * Proper blood, liver, renal, heart function: testing result within 2 weeks from registry of this study as follows: 1. White Blood Cell (WBC) \>3,000 cells/mm3 2. Absolute neutrophil count ≥1500/mm3 3. International Normalized Ratio (INR) \<2.0 4. Partial Thromboplastin Time (PTT) \<40 sec 5. Platelet count \>50,000/mm3 6. Blood bilirubin \<3.0 mg/dL 7. Aspartate Aminotransferase (AST) and/or Alanine Aminotransferase (ALT) is within 5 times of normal range of each organ 8. Serum creatinine \<1.5 mg/dL 9. Hemoglobin \>8.0 g/dL 10. Alkaline phosphatase \<630 IU/L 11. No unstable coronary artery disease or recent Myocardial Infarction(MI) 12. Normal electrocardiogram (ECG) with QT interval \<480 msec within the previous 12 months 13. No current infections requiring antibiotic therapy 14. Not on anticoagulation or suffering from a known bleeding disorder. * Measureable disease per mRECIST. * Expected survival more than 3 months Exclusion Criteria: * ECOG performance status \>2; or Child-Pugh class\>11 points or more, or American Society of Anaesthesiologists' (ASA) class 5 . * Bilirubin levels \>3 mg/dL * mCRC within the large vessel or biliary duct invasion, diffuse hepatocellular carcinoma (HCC) or extrahepatic spread. * Patients in which any of the following are contraindicated or present: 1. The use of irinotecan 2. MRI or CT scans 3. Hepatic embolization procedures 4. WBC \<3000 cells/mm3 5. neutrophil \<1500 cells/mm3 6. Cardiac ejection fraction \<50% assessed by isotopic ventriculography, echocardiography or MRI 7. Elevated serum creatinine ≥ 2.5 mg/dL 8. Impaired clotting test (platelet count \< 50,000/mm3, PT-INR \>2.0 9. AST and/or ALT \>5x upper limit of normal (ULN), when greater \>250 U/I 10. Known hepatofugal blood flow. 11. Arterio-venous shunt 12. Arterio-portal shunt 13. Main stem portal vein occlusion * Women who are pregnant or nursing * Allergy to iodinated contrast used for angiography * Tumour burden of more than 50% of liver volume (Tumor volume by be smaller e.g. ≤30%) * Patients with active bacterial, viral (HIV), or fungal infection. * Other malignancies * Any co-morbid disease or condition or event that, in the investigator's judgment, would place the patient a undue risk what would preclude the safe use of DEB-TACE.